CN107205964A - 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 - Google Patents

使用调节释放索拉贝隆用于下尿路症状的组合物和方法 Download PDF

Info

Publication number
CN107205964A
CN107205964A CN201580074649.0A CN201580074649A CN107205964A CN 107205964 A CN107205964 A CN 107205964A CN 201580074649 A CN201580074649 A CN 201580074649A CN 107205964 A CN107205964 A CN 107205964A
Authority
CN
China
Prior art keywords
pharmaceutical composition
release
hours
sorabegron
max
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580074649.0A
Other languages
English (en)
Chinese (zh)
Inventor
E·奥斯特恩
R·E·史蒂文斯
H·J·威尔金斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Velicept Therapeutics Inc
Original Assignee
Velicept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Velicept Therapeutics Inc filed Critical Velicept Therapeutics Inc
Publication of CN107205964A publication Critical patent/CN107205964A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580074649.0A 2014-12-03 2015-12-03 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 Pending CN107205964A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462087021P 2014-12-03 2014-12-03
US62/087,021 2014-12-03
PCT/US2015/063795 WO2016090168A1 (en) 2014-12-03 2015-12-03 Compositions and methods of using modified release solabegron for lower urinary tract symptoms

Publications (1)

Publication Number Publication Date
CN107205964A true CN107205964A (zh) 2017-09-26

Family

ID=56092482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580074649.0A Pending CN107205964A (zh) 2014-12-03 2015-12-03 使用调节释放索拉贝隆用于下尿路症状的组合物和方法

Country Status (12)

Country Link
US (3) US9956194B2 (https=)
EP (1) EP3226849A4 (https=)
JP (1) JP2017537165A (https=)
KR (1) KR20170086659A (https=)
CN (1) CN107205964A (https=)
AU (1) AU2015358378A1 (https=)
CA (1) CA2969405A1 (https=)
EA (1) EA201791225A1 (https=)
HK (1) HK1245117A1 (https=)
IL (1) IL252628A0 (https=)
MX (1) MX2017007054A (https=)
WO (1) WO2016090168A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
WO2017210700A1 (en) * 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
BR112019004935A2 (pt) 2016-09-13 2019-06-04 Allergan, Inc. composições de toxina clostridial não proteíca estabilizada
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
KR102940911B1 (ko) 2018-12-05 2026-03-17 유로반트 사이언시즈 게엠베하 과민성 방광 증상의 치료를 위한 비베그론
US20240197660A1 (en) * 2021-03-31 2024-06-20 B3Ar Therapeutics, Inc. Compositions of micronized solabegron and methods of use
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
CN103269692A (zh) * 2010-08-03 2013-08-28 奥瑟克斯公司 用于治疗膀胱过度活动症的β-3肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂的药物组合

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (https=) 1960-07-26
EP0006735B1 (en) 1978-06-28 1983-06-15 Beecham Group Plc Secondary amines, their preparation, pharmaceutical compositions containing them and their use
GB8519154D0 (en) 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
JPH0236571B2 (ja) * 1986-04-11 1990-08-17 Otsuka Pharma Co Ltd Jizokuseiseizai
DE3934436A1 (de) 1989-06-01 1991-04-18 Thomae Gmbh Dr K 2-hydroxy-n-propylamine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5061727A (en) 1990-05-04 1991-10-29 American Cyanamid Company Substituted 5-(2-((2-aryl-2-hydroxyethyl)amino)propyl)-1,3-benzodioxoles
NO179246C (no) 1991-11-20 1996-09-04 Sankyo Co Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
WO1995033724A1 (en) 1994-06-09 1995-12-14 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
US20060240105A1 (en) * 1998-11-02 2006-10-26 Elan Corporation, Plc Multiparticulate modified release composition
EP1126826B3 (en) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Multiparticulate modified release composition of methylphenidate
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
US6444685B1 (en) 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US7709677B2 (en) 2001-01-31 2010-05-04 Glaxosmithkline Llc Process of preparing arylethanoldiamines
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
US7034053B2 (en) 2001-01-31 2006-04-25 Smithkline Beecham Corporation Phenethanolamine derivatives, compositions, and their use as agonists at atypical beta-adrenoreceptors
NZ527832A (en) * 2001-03-13 2006-03-31 Penwest Pharmaceuticals Co Chronotherapeutic dosage forms
WO2003024483A1 (fr) 2001-09-11 2003-03-27 Fujisawa Pharmaceutical Co., Ltd. Potentialisateur d'effets inhibiteurs sur la frequence des mictions et l'incontinence urinaire
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
AU2004285289A1 (en) 2003-11-03 2005-05-12 Boehringer Ingelheim International Gmbh Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor
DE10352132A1 (de) 2003-11-04 2005-06-09 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
JP4838724B2 (ja) 2003-11-27 2011-12-14 デヴェロゲン アクチエンゲゼルシャフト ニュールツリンを用いる糖尿病の予防と治療方法
AU2004312059A1 (en) 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
EP1550447A1 (en) 2004-01-02 2005-07-06 Schering Aktiengesellschaft Menstrual cycle control and improvement of conception rates in females
WO2005077364A1 (ja) 2004-02-18 2005-08-25 Yamanouchi Pharmaceutical Co., Ltd. ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
WO2006042679A1 (de) 2004-10-18 2006-04-27 Boehringer Ingelheim International Gmbh Verwendung eines beta-3-agonisten zur behandlung von beschwerden der prostata und des unteren urogenitaltrakts
CA2606207C (en) 2005-04-19 2014-11-18 Smithkline Beecham (Cork) Limited Pharmaceutical composition
EP1769792A1 (de) 2005-09-30 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co.KG Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden
ITMI20061581A1 (it) 2006-08-04 2008-02-05 Univ Bari Ligandi del recettore beta-3 adrenergico e loro uso in terapia
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
WO2008121268A1 (en) 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
GB0714790D0 (en) * 2007-07-30 2007-09-12 Jagotec Ag Improvements in or relating to organic compounds
DK2216021T3 (da) 2007-11-02 2012-11-05 Astellas Pharma Inc Farmaceutisk sammensætning til behandling af overaktiv blære
AU2009231967B2 (en) 2008-04-04 2013-02-07 Merck Sharp & Dohme Corp. Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2181707A1 (en) 2008-11-04 2010-05-05 Astellas Ireland Co., Ltd. Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
US8778998B2 (en) 2009-04-10 2014-07-15 Auspex Pharmaceuticals, Inc. Biphenyl-3-carboxylic acid modulators of beta-3-adrenoreceptor
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US8618144B2 (en) 2009-05-08 2013-12-31 Merck Sharp & Dohme Corp Pyrrolidine-derived beta 3 adrenergic receptor agonists
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
MX2012002366A (es) 2009-08-27 2012-03-29 Merck Sharp & Dohme Agonistas novedosos de receptores beta 3 andrenergicos derivados de pirrolidina.
US8354403B2 (en) 2009-08-27 2013-01-15 Merck Sharp & Dohme Corp. Pyrrolidine derived beta 3 adrenergic receptor agonists
NZ599233A (en) 2009-10-07 2013-04-26 Merck Sharp & Dohme Combination therapy using a beta 3 adrenergic receptor agonist and an antimuscarinic agent
JP5812500B2 (ja) 2010-04-30 2015-11-17 メルク・シャープ・エンド・ドーム・コーポレイション 新規なβ３アドレナリン作動性受容体アゴニスト
US9522129B2 (en) * 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
WO2016004056A1 (en) 2014-07-03 2016-01-07 Velicept Therapeutics, Inc. Pharmaceutical combinations
US20120289560A1 (en) 2011-05-10 2012-11-15 Theravida, Inc. Combinations of tolterodine and salivary stimulants for the treatment of overactive bladder
SG11201404776PA (en) 2012-02-09 2014-09-26 Altherx Inc Combination of muscarinic receptor antagonists and beta- 3 adrenoceptor agonists for treating overactive bladder
EA201590449A1 (ru) 2012-08-31 2015-06-30 Астеллас Фарма Инк. Перорально вводимая лекарственная композиция
US20150306170A1 (en) 2012-11-21 2015-10-29 Ferring B.V. Composition for immediate and extended release
US20150158809A9 (en) 2013-02-26 2015-06-11 Xenoport, Inc. Method of making 1-(acyloxy)-alkyl carbamate compounds
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
KR20160033220A (ko) 2013-07-23 2016-03-25 알러간, 인코포레이티드 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
US10166183B2 (en) 2014-02-07 2019-01-01 Auspex Pharmaceuticals, Inc. Pharmaceutical formulations
JP2017078023A (ja) 2014-02-28 2017-04-27 アステラス製薬株式会社 経口投与用医薬組成物
CN107205964A (zh) 2014-12-03 2017-09-26 威力塞帕特治疗股份有限公司 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
EP3448366A1 (en) 2016-04-25 2019-03-06 Synthon B.V. Modified release tablet composition comprising mirabegron
WO2017210700A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
WO2017210696A1 (en) 2016-06-03 2017-12-07 Velicept Therapeutics, Inc. Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101242813A (zh) * 2005-06-20 2008-08-13 依兰药物国际有限公司 包含芳基-杂环化合物的毫微粒和控制释放组合物
CN103269692A (zh) * 2010-08-03 2013-08-28 奥瑟克斯公司 用于治疗膀胱过度活动症的β-3肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂的药物组合

Also Published As

Publication number Publication date
EP3226849A1 (en) 2017-10-11
WO2016090168A1 (en) 2016-06-09
US20160158176A1 (en) 2016-06-09
EA201791225A1 (ru) 2017-12-29
US9956194B2 (en) 2018-05-01
US20190083433A1 (en) 2019-03-21
IL252628A0 (en) 2017-07-31
US10751311B2 (en) 2020-08-25
EP3226849A4 (en) 2018-05-09
CA2969405A1 (en) 2016-06-09
JP2017537165A (ja) 2017-12-14
US20190083434A1 (en) 2019-03-21
MX2017007054A (es) 2018-05-02
AU2015358378A1 (en) 2017-06-29
KR20170086659A (ko) 2017-07-26
HK1245117A1 (zh) 2018-08-24

Similar Documents

Publication Publication Date Title
CN107205964A (zh) 使用调节释放索拉贝隆用于下尿路症状的组合物和方法
US20170348263A1 (en) Compositions and methods of using modified release solabegron for lower urinary tract symptoms
AU2003225837B2 (en) NE and 5-HT reuptake inhibitors for treating visceral pain syndromes
US20170348288A1 (en) Dosing regimens for beta-3 adrenoceptor agonists and anti-muscarinic agents for the treatment and prevention of lower urinary tract symptoms and overactive bladder
TWI247605B (en) Combinations for the treatment of immunoinflammatory disorders
US20130095180A1 (en) Time-delayed sustained release pharmaceutical composition comprising dapoxetine for oral administration
JP2014169303A (ja) オキシコドンおよびナロキソンを含有する剤形
TW200404549A (en) Novel methods and compositions for alleviating pain
JPH11504902A (ja) ヒトの性的応答を調節するための方法及び製剤
JP2003095979A (ja) ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置
TW200808324A (en) Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload
US20060293309A1 (en) Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
KR20180104123A (ko) 비알콜성 지방간염 (NASH)의 치료를 위한 sGC 자극제의 용도
CZ299712B6 (cs) Použití dapoxetinu pro zvládnutí sexuální dysfunkce podáváním zpusobem podle potreby
CN104780915A (zh) 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
JP2006511624A (ja) α２δサブユニット・カルシウム・チャンネル調節因子を使用する無痛性膀胱障害を処置するための方法
BG64888B1 (bg) Фармацевтични комбинации с трамадол
JP2022179727A (ja) リナクロチドの改変または標的放出製剤
JP2022075670A (ja) ネコの全身性疾患の予防又は治療用アンジオテンシンｉｉ受容体拮抗薬
EA007952B1 (ru) Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
EP0694299A1 (en) The use of( a) bicycloheptane derivative(s)
CN118574630A (zh) 姜黄素组合物和作为nk3拮抗剂的使用方法
MX2010006520A (es) Metodo y composicion para el tratamiento de una condicion mediada por alfa-adrenoceptor.
JP2022542698A (ja) セロトニン作動薬及び５－ｈｔ１ａ受容体アンタゴニスト
WO2012030314A1 (en) Compositions comprising 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine, and methods of administering same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20170926

WD01 Invention patent application deemed withdrawn after publication